SCHEMBL568430

SCHEMBL568430

CCCCCCOC(Cl)Cl

nearest known ligand 0.52

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 1/20 0.52
THRB P10828 2/20 0.42
TSHR P16473 2/20 0.42
MEN1 O00255 1/20 0.39
HTT P42858 1/20 0.39
KMT2A Q03164 1/20 0.39
MAPT P10636 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LPAR1 Q92633 6/20 0.39
LPAR3 Q9UBY5 6/20 0.39
LPAR2 Q9HBW0 2/20 0.39
USP2 O75604 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11533725 1.00 DNM1 (0.52) DNM1THRBTSHRMEN1HTT
SCHEMBL8467889 0.97
SCHEMBL2108013 0.89
SCHEMBL11691580 0.82 DNM1 (0.50) DNM1THRBTSHRMEN1HTT
SCHEMBL11788485 0.82 DNM1 (0.50) DNM1THRBTSHRMEN1HTT
SCHEMBL9627846 0.81 DNM1 (0.48) DNM1THRBTSHRMEN1HTT
SCHEMBL9714692 0.80 DNM1 (0.48) DNM1THRBTSHRMEN1HTT
SCHEMBL9714750 0.80 DNM1 (0.48) DNM1THRBTSHRMEN1HTT
Ammonia Solution, Strong SCHEMBL8616329 0.80 DNM1 (0.48) DNM1THRBTSHRMEN1HTT
SCHEMBL27462497 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352376-B2 Catalysts BOREALIS AG (AT) 2022-06-07 US disclosed
EP-3541823-B1 CATALYSTS BOREALIS AG (AT) 2020-12-30 EP disclosed
US-20190308995-A1 CATALYSTS BOREALIS AG (AT) 2019-10-10 US disclosed
EP-3541823-A1 CATALYSTS Borealis AG (AT) 2019-09-25 EP disclosed
EP-2722345-B1 CATALYST FOR THE POLYMERISATION OF OLEFINS BOREALIS AG (AT) 2018-12-05 EP disclosed
CN-108409895-A Catalyst 博瑞立斯有限公司 2018-08-17 CN disclosed
WO-2018091684-A1 CATALYSTS BOREALIS AG (AT) 2018-05-24 WO disclosed
EP-2729479-B1 CATALYSTS BOREALIS AG (AT) 2017-09-06 EP disclosed
US-9630980-B2 Asymmetrical ligands BOREALIS AG (AT) 2017-04-25 US disclosed
US-9567351-B2 Heterophasic copolymers BOREALIS AG (AT) 2017-02-14 US disclosed
EP-0420237-A1 Biphenylmethane derivative, the use of it and pharmacological compositions containing same Eisai Co., Ltd. (JP) 1991-04-03 EP disclosed
US-4981509-A Plant growth regulators E. I. DU PONT DE NEMOURS AND COMPANY (US) 1991-01-01 US disclosed
US-4927826-A Cycloproylpropenamides useful as platelet activing factor (PAF) antagonists HOFFMAN-LA ROCHE INC. (US) 1990-05-22 US disclosed
US-4871847-A Herbicidal sulfonamides E. I. DU PONT DE NEMOURS AND COMPANY (US) 1989-10-03 US disclosed
US-4849010-A Herbicidal sulfonamides E. I. DUPONT DE NEMOURS AND COMPANY (US) 1989-07-18 US disclosed
US-4802908-A Herbicidal 2-(1H)-pyrazinones E. I. DU PONT DE NEMOURS AND COMPANY (US) 1989-02-07 US disclosed
US-4786646-A PLATELET ACTIVATING FACTOR ANTAGONISTS HOFFMANN-LA ROCHE INC. (US) 1988-11-22 US disclosed
US-4724039-A RICE CROP E. I. DU PONT DE NEMOURS AND COMPANY (US) 1988-02-09 US disclosed
US-4710221-A Herbicidal sulfonamides E. I. DU PONT DE NEMOURS AND COMPANY (US) 1987-12-01 US disclosed
EP-0162723-A2 Herbicidal sulfonamides E.I. DU PONT DE NEMOURS AND COMPANY (US) 1985-11-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11352376-B2 Catalysts SIGMAR1, H1-2, SFN DNM1 3082/4885THRB 1384/4885TSHR 560/4885
US-20190308995-A1 CATALYSTS SIGMAR1, H1-2, CBR1 DNM1 3201/4885THRB 1506/4885TSHR 689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.